HomeBUSINESS
BUSINESS

Daiichi Sankyo/Kite’s CAR-T Cell Therapy Scoops Up Orphan Status for B-Cell Lymphoma
(Oct.4.2018)

Daiichi Sankyo said on October 3 that the CAR-T therapy axicabtagene ciloleucel (development code: KTE-C19) has earned orphan drug status in Japan for the treatment of certain types of B-cell lymphoma ...
(LOG IN FOR FULL STORY)